The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
16-Feb-23
Pending
$220 million
Target:
Flavor Specialty Ingredients division of IFF
Acquiror:
Exponent Private Equity
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
10-Feb-23
Pending
$415 million
Target:
Gaming Services Division of Global Payments
Acquiror:
Parthenon Capital
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
03-Nov-22
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
MVolution Partners
Advised Pixelligent Technologies, a leading manufacturer of nanocrystal material used in consumer electronic devices, on its growth capital raise
25-Oct-22
Pending
Undisclosed
Target:
Acreage Holdings
Acquiror:
Canopy Growth Corporation
Advising Canopy Growth, a leading diversified cannabis company, on the re-organization and consolidation of its U.S. cannabis assets under a new holding company, Canopy USA, and on related investments and debt repurchase transactions
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
08-Aug-22
Pending
$3.0 billion
Target:
InSinkErator (Emerson Electric)
Acquiror:
Whirlpool Corporation
Advised Whirlpool Corporation on its announced acquisition of InSinkErator, the world’s largest manufacturer of food waste disposers and instant hot water dispensers for home and commercial use from Emerson Electric for cash consideration of $3.0 billion
30-Jun-22
Undisclosed
Target:
Sands Family
Acquiror:
Constellation Brands, Inc
Advised the Sands Family in connection with the elimination of Constellation Brands' Class B common stock, which included the conversion of each share of Class B common stock into the right to receive one share of Class A common stock plus $64.64 in cash consideration
30-Jun-22
~$210 million
Target:
Liontown Resources
Acquiror:
Offtake Agreement and Financing Facility from Ford Motor Company
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company
19-Apr-22
Pending
$107 million
Target:
Syrah Resources
Acquiror:
U.S. Department of Energy
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
01-Feb-22
Undisclosed
Target:
Alteon Health
Acquiror:
U.S. Acute Care Solutions
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
28-Jan-22
Undisclosed
Target:
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Acquiror:
Laboratoires Théa SAS
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
20-Jan-22
Pending
Undisclosed
Target:
GrowFlow Corp.
Acquiror:
Dama Financial
Advising Dama Financial, the nation’s largest provider of access to banking and payment solutions for the cannabis industry, on its acquisition of GrowFlow Corp, a leading business management and compliance software platform for cannabis retailers, cultivators, processors, and distributors
08-Dec-21
$240 million
Target:
Alert 360
Acquiror:
My Alarm Center
Advising My Alarm Center, a nationwide provider of security and smart home monitoring services, on the acquisition of Alert 360, a leading competitor in the alarm monitoring industry
12-Nov-21
Undisclosed
Target:
Grupo Totalmédia
Acquiror:
Consortium of Private Investors Led by the Management Team
Advised Explorer Investments on the sale of Grupo Totalmédia, the leading specialist logistics player in Iberia operating in two-man home delivery, assembly and installation of furniture, heavy goods and groceries as well as the distribution of autoparts and leaflets
10-Nov-21
Undisclosed
Target:
Bell's Brewery
Acquiror:
Lion / Kirin
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
05-Nov-21
$240 million
Target:
MetalX, Inc.
Acquiror:
BlueScope Steel Limited
Advised MetalX, Inc., a leading ferrous and non-ferrous metal scrap recycling company, on the sale of substantially all of its ferrous scrap processing business to BlueScope Steel Limited, an Australian-listed provider of steel materials, products, systems and technologies
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"